MOVIPREP Drug Patent Profile

When do Moviprep patents expire, and what generic alternatives are available?

Moviprep is a drug marketed by Salix Pharms and is included in one NDA.

The generic ingredient in MOVIPREP is ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate profile page.

Summary for MOVIPREP

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	40
Drug Prices:	Drug price information for MOVIPREP
Drug Sales Revenues:	Drug sales revenues for MOVIPREP
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MOVIPREP
What excipients (inactive ingredients) are in MOVIPREP?	MOVIPREP excipients list
DailyMed Link:	MOVIPREP at DailyMed

See drug prices for MOVIPREP

See drug sales revenues for MOVIPREP

Recent Clinical Trials for MOVIPREP

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
North Denmark Regional Hospital	Phase 4
Aalborg University Hospital	Phase 4
Radboud University Medical Center	N/A

See all MOVIPREP clinical trials

Paragraph IV (Patent) Challenges for MOVIPREP

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MOVIPREP	For Oral Solution	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate	100 g, 7.5 g, 2.691 g, 1.015 g, 5.9 g and 4.7 g per pouch	021881	1	2007-11-27

US Patents and Regulatory Information for MOVIPREP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Salix Pharms	MOVIPREP	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate	FOR SOLUTION;ORAL	021881-001	Aug 2, 2006	AA	RX	Yes	Yes

Expired US Patents for MOVIPREP

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Salix Pharms	MOVIPREP	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate	FOR SOLUTION;ORAL	021881-001	Aug 2, 2006
Salix Pharms	MOVIPREP	ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate	FOR SOLUTION;ORAL	021881-001	Aug 2, 2006

International Patents for MOVIPREP

See the table below for patents covering MOVIPREP around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	E045881
Germany	03758361
Germany	20321510
Russian Federation	2353412	СУХАЯ КОМПОЗИЦИЯ ДЛЯ СМЕШИВАНИЯ С ВОДОЙ, ОЧИСТИТЕЛЬНЫЙ ПРЕПАРАТ (ВАРИАНТЫ), НАБОР КОМПОНЕНТОВ ДЛЯ ОЧИСТКИ ТОЛСТОЙ КИШКИ (ВАРИАНТЫ), ПОЛИЭТИЛЕНГЛИКОЛЬ В КАЧЕСТВЕ СРЕДСТВА ДЛЯ ОЧИСТКИ ТОЛСТОЙ КИШКИ (ВАРИАНТЫ) И СПОСОБ ОЧИЩЕНИЯ ТОЛСТОЙ КИШКИ (ВАРИАНТЫ) (POWDER/WATER MIXTURE, CLEANING AGENT (VERSIONS), COMPONENT SET FOR LARGE INTESTINE DEPLETION (VERSIONS), POLYETHYLENE GLYCOL AS LARGE INTESTINE DEPLETION AGENT (VERSIONS) AND METHOD OF LARGE INTESTINE DEPLETION (VERSIONS))
Japan	4784770
Canada	2672427	COMPOSITIONS DE NETTOYAGE DU COLON (COLON CLEANSING COMPOSITIONS)

Supplementary Protection Certificates for MOVIPREP

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3141251	C202130017	Spain		PRODUCT NAME: COMBINACION DE PRINCIPIOS ACTIVOS EN DOS DOSIS, EN LA QUE LA PRIMERA DOSIS CONSISTE EN LOS PRINCIPIOS ACTIVOS POLIETILENGLICOL, SULFATO DE SODIO, CLORURO DE SODIO Y CLORURO DE POTASIO, Y LA SEGUNDA DOSIS CONSISTE EN LOS PRINCIPIOS ACTIVOS POLIETILENGLICOL, ACIDO ASCORBICO, ASCORBATO DE SODIO, CLORURO DE SODIO Y CLORURO DE POTASIO.; NATIONAL AUTHORISATION NUMBER: 82959-SE/H/1801/001/DC; DATE OF AUTHORISATION: 20180525; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): IS/1/17/083/01; DATE OF FIRST AUTHORISATION IN EEA: 20171016
3141251	301099	Netherlands		PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016
3141251	132021000000044	Italy		PRODUCT NAME: UN PRODOTTO MEDICINALE COSTITUITO DA UNA COMBINAZIONE DI UNA PRIMA DOSE DI COMPOSIZIONE FARMACEUTICA E UNA SECONDA DOSE DI COMPOSIZIONE FARMACEUTICA, LA PRIMA DOSE DI COMPOSIZIONE FARMACEUTICA E COSTITUITA DAGLI INGREDIENTI ATTIVI POLIETILENGLICOLE, SOLFATO DI SODIO, CLORURO DI SODIO E CLORURO DI POTASSIO E LA SECONDA DOSE DI COMPOSIZIONE FARMACEUTICA E COSTITUITA DAGLI INGREDIENTI ATTIVI POLIETILENGLICOLE, ACIDO ASCORBICO, ASCORBATO DI SODIO, CLORURO DI SODIO E CLORURO DI POTASSIO.(PLENVU); AUTHORISATION NUMBER(S) AND DATE(S): IS/1/17/083/01, 20171016;045671017, 045671029, 045671031, 045671043, 045671056, 20171213

Market Dynamics and Financial Trajectory for MOVIPREP

Last updated: July 27, 2025

Introduction

MOVIPREP, a prominent bowel preparation agent indicated for colon cleansing before colonoscopy procedures, has established itself within the highly competitive gastrointestinal (GI) medication segment. As a combination of polyethylene glycol (PEG) with ascorbate and sodium chloride, MOVIPREP's efficacy, safety profile, and convenience have driven its adoption globally. This analysis explores the current market dynamics influencing MOVIPREP, evaluates its financial trajectory, and assesses strategic factors shaping its future.

Market Overview

The global gastrointestinal (GI) drugs market is projected to reach approximately USD 35 billion by 2025, with colonoscopy preparations constituting a significant segment. The rising prevalence of colorectal cancer (CRC), gastrointestinal disorders, and increased screening programs have amplified demand for bowel cleansing agents. MOVIPREP, introduced by Ferring Pharmaceuticals, commands a substantial share owing to its improved tolerability compared to older PEG formulations.

Key Drivers of Market Growth

• Increase in Colorectal Cancer Screening: Globally, CRC remains a leading cause of cancer-related mortality. Regular screenings necessitate effective bowel prep, amplifying demand for agents like MOVIPREP [1].

• Rising Incidence of GI Disorders: Conditions requiring colonoscopy, such as inflammatory bowel disease (IBD), propel usage rates.

• Patient Preference for Convenience: MOVIPREP's taste-masking and dosing regimen address previous patient compliance issues with traditional PEG solutions.

• Expanding Age Demographics: An aging population predisposed to colorectal pathologies bolsters market expansion.

• Regulatory Approvals and Healthcare Investments: Growing acceptance in emerging markets, facilitated by regulatory approvals, continues to open new revenue avenues.

Market Challenges

• Competitive Landscape: Presence of alternatives like Pico-Salax, Suprep, and OTC options impacts market share.

• Cost Considerations: Higher costs relative to generic PEG formulations may limit adoption in price-sensitive regions.

• Patient Compliance and Tolerance: Despite improvements, adverse effects and taste issues remain potential barriers.

Financial Trajectory Analysis

Revenue Trends

Ferring Pharmaceuticals has reported steady growth in MOVIPREP revenues, driven by expanding indications and geographic reach. Global sales historically grew mid-single digits annually, with notable expansion in Asia-Pacific and Latin America, where colorectal screening programs intensify [2].

Pricing Strategies

Ferring leverages premium pricing aligned with its product quality and convenience benefits. However, price erosion due to increased generic competition, especially in mature markets, presents a potential risk to profit margins.

Market Penetration and Adoption

In developed markets such as North America and Europe, MOVIPREP enjoys a high adoption rate due to entrenched clinical guidelines and insurance coverage. Emerging markets are witnessing growing adoption, often facilitated by local partnerships and educational campaigns.

Pipeline and Innovation Impact

Ferring continues to innovate, aiming to develop next-generation bowel prep formulations with improved taste, dosing, and minimal side effects. These efforts could further enhance market share and revenue streams, aligning with the broader trend of patient-centered GI solutions.

Impact of Regulatory Changes

Stringent regulatory standards, especially regarding safety and efficacy documentation, influence market entry and expansion strategies. Positive regulatory decisions bolster revenue prospects, whereas delays or rejections could hinder growth.

Potential Market Challenges

• Patent Expirations: Loss of exclusivity could lead to increased biosimilar or generic competition, exerting downward pressure on prices.

• Reimbursements and Healthcare Policies: Shifts towards value-based care and reimbursement caps may impact profitability.

• Market Saturation: In mature markets, slow growth may necessitate diversification into related GI therapeutics.

Future Outlook and Strategic Considerations

The outlook for MOVIPREP remains cautiously optimistic. Continued emphasis on clinical data supporting safety, tolerability, and efficacy is essential. Expansion into unserved or underpenetrated markets could provide substantial revenue growth. Moreover, partnerships with healthcare providers and payers to emphasize cost-effectiveness and improved patient outcomes will be critical.

Ferring's ongoing R&D investments aimed at optimizing bowel preparation could redefine the market standard, influencing pricing and adoption. Additionally, engaging in educational campaigns to improve patient compliance has potential to boost prescription rates.

Key Market Trends Impacting Financial Trajectory

• Digital and Telehealth Integration: Facilitates wider dissemination of patient education and adherence programs.

• Personalized Medicine Approaches: Tailoring bowel prep to patient profiles could enhance efficacy and reduce adverse effects, creating a competitive advantage.

• Emerging Market Expansion: Growth opportunities in Asia-Pacific, Middle East, and Latin America are meteoric given expanding healthcare infrastructure.

• Regulatory and Reimbursement Incentives: Favorable policies can accelerate product uptake and revenue growth.

Conclusion

MOVIPREP's market dynamics are characterized by steady demand driven by escalating colorectal cancer screening and advancements in formulation technology. The financial trajectory indicates potential for sustained growth, contingent upon strategic positioning amidst competitive pressures and evolving healthcare policies. Ferring Pharmaceuticals' focus on innovation, geographic expansion, and stakeholder engagement will determine its capacity to capitalize on these opportunities.

Key Takeaways

• The global GI drug market is expanding, with colonoscopy preparations like MOVIPREP positioned for continued growth due to rising CRC screening rates.

• Competitive landscape and pricing pressures necessitate ongoing innovation and strategic marketing.

• Geographic diversification, especially in emerging markets, remains vital for revenue growth.

• Regulatory developments and reimbursement policies significantly influence the financial outlook.

• Investment in patient-centered formulations and digital health integration can offer competitive advantages for sustained market share.

FAQs

1. How does MOVIPREP compare to other bowel cleansing agents?
MOVIPREP offers improved taste and dosing convenience over traditional PEG solutions, with a safety profile suitable for most patients. However, competing agents like Suprep and Pico-Salax may offer different dosing regimens or cost benefits.

2. What are the primary factors influencing MOVIPREP's market growth?
Key factors include increasing colorectal cancer screening programs, patient preferences for convenient dosing, expanding healthcare infrastructure in emerging markets, and ongoing innovation by manufacturers.

3. What challenges does MOVIPREP face in the evolving pharmaceutical landscape?
Challenges encompass generic competition, pricing pressures, regulatory hurdles, and shifts in healthcare policies emphasizing cost-effectiveness.

4. How is Ferring Pharmaceuticals positioning MOVIPREP for future growth?
Ferring is investing in product innovation, expanding access in emerging markets, building strategic partnerships, and emphasizing educational initiatives to improve compliance and adoption.

5. What is the outlook for MOVIPREP’s revenue in the next five years?
Assuming successful execution of expansion and innovation strategies, MOVIPREP's revenues are projected to grow at a low to mid-single-digit CAGR, driven by market expansion and product enhancements, barring significant regulatory or competitive disruptions.

---

Sources:
[1] Global Gastrointestinal Drugs Market Reports. (2022). MarketWatch.
[2] Ferring Pharmaceuticals Annual Report. (2022).